Payment overview · 2025
General Payments
$1,119.02
19 reported records · 11 companies
Healthcare provider profile · identity verified
Rita Suharli
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · ALBUQUERQUE, NM · NPI 1659724193
Verified facts
What the public records show
CMS Open Payments records show Rita Suharli received $1,119.02 in general payments during 2025 across 19 reported records.
Novo Nordisk Inc accounted for 24.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $273.86 | 24.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $269.77 | 24.1% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $118.70 | 10.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $118.30 | 10.6% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $114.05 | 10.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $96.32 | 8.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.73 | 4.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $29.71 | 2.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.49 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.92 | 1.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.17 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,119.02 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $259.04 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $132.48 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $123.15 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $118.70 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $118.30 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $114.05 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $96.32 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $44.73 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $29.71 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $10.73 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $10.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
40 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
85 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 668 | 178 |
| Atorvastatin Calcium | Atorvastatin Calcium | 518 | 148 |
| Lisinopril | Lisinopril | 418 | 135 |
| Losartan Potassium | Losartan Potassium | 275 | 77 |
| Gabapentin | Gabapentin | 270 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 266 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 242 | 71 |
| Metformin Hcl | Metformin Hcl | 200 | 68 |
| Omeprazole | Omeprazole | 197 | 60 |
| Simvastatin | Simvastatin | 173 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 49 |
| Alendronate Sodium | Alendronate Sodium | 159 | 44 |
| Montelukast Sodium | Montelukast Sodium | 154 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 149 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 133 | 52 |
| Jardiance | Empagliflozin | 116 | 33 |
| Trazodone Hcl | Trazodone Hcl | 112 | 33 |
| Famotidine | Famotidine | 97 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 94 | 17 |
| Sertraline Hcl | Sertraline Hcl | 94 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 86 | 17 |
| Eliquis | Apixaban | 85 | 20 |
| Furosemide | Furosemide | 82 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 38 |
| Baclofen | Baclofen | 73 | 19 |
| Meloxicam | Meloxicam | 71 | 25 |
| Potassium Chloride | Potassium Chloride | 70 | 20 |
| Allopurinol | Allopurinol | 69 | 22 |
| Celecoxib | Celecoxib | 65 | 24 |
| Tramadol Hcl | Tramadol Hcl | 64 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 22 |
| Atenolol | Atenolol | 57 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 18 |
| Ibuprofen | Ibuprofen | 57 | 25 |
| Acyclovir | Acyclovir | 54 | 20 |
| Lovastatin | Lovastatin | 53 | 15 |
| Ozempic | Semaglutide | 53 | suppressed |
| Prednisone | Prednisone | 53 | 40 |
| Metformin Hcl Er | Metformin Hcl | 51 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 49 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 13 |
| Synthroid | Levothyroxine Sodium | 48 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 19 |
| Alprazolam | Alprazolam | 45 | suppressed |
| Bupropion Xl | Bupropion Hcl | 45 | 11 |
| Finasteride | Finasteride | 45 | 14 |
| Lorazepam | Lorazepam | 45 | 11 |
| Spironolactone | Spironolactone | 44 | 16 |
| Carvedilol | Carvedilol | 43 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | 12 |
| Azithromycin | Azithromycin | 37 | 31 |
| Estradiol | Estradiol | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 28 |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | suppressed |
| Glipizide Er | Glipizide | 33 | 12 |
| Glipizide | Glipizide | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | 11 |
| Desmopressin Acetate | Desmopressin Acetate | 30 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 12 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 18 |
| Felodipine Er | Felodipine | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Nystatin | Nystatin | 16 | 13 |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,119.02 · 19 records | Novo Nordisk Inc | ABRYSVO, AREXVY, BREZTRI, COMIRNATY, EVENITY, MOUNJARO, OTEZLA, Omnipod, Ozempic, PREVNAR 20, PROLIA, REPATHA, REXULTI, SHINGRIX, The Cologuard Plus Collection Kit, VOQUEZNA, Veozah, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error